Abstract
Patient Reported Outcomes for SB5, an adalimumab biosIMILAR, in patients with rheumatoid arthritis and ankylosing spondylitis (PRO-SIMILAR): Study protocol for a phase IV, single-arm, open-label trial
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have